Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults (EPACRA-AKI)

NCT06652100 is registered in ClinicalTrials.gov with BioPorto Diagnostics as lead sponsor.

NCT NCT06652100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06652100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults (EPACRA-AKI)
Lead sponsor
BioPorto Diagnostics
Phase
Observational
Overall status
Active, not recruiting
Start date
October 28, 2024
Completion date
January 31, 2026
Enrollment
800 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury